Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy

Morgan Hakki; Janet F Staab; Kieren A Marr

doi:10.1128/AAC.00148-06

Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy

Antimicrob Agents Chemother. 2006 Jul;50(7):2522-4. doi: 10.1128/AAC.00148-06.

Authors

Morgan Hakki¹, Janet F Staab, Kieren A Marr

Affiliation

¹ Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA.

Abstract

Clinical failure associated with reduced susceptibility to caspofungin has been described in Candida albicans and C. parapsilosis. We report a case of Candida krusei infection that progressed despite caspofungin therapy. Reduced microbial susceptibility to all three echinocandins (caspofungin, anidulafungin, and micafungin) was noted but was not associated with mutations in FKS1.

Publication types

Case Reports

MeSH terms

Adult
Antifungal Agents / pharmacology*
Antifungal Agents / therapeutic use
Candida / drug effects*
Candida / isolation & purification
Candidiasis, Oral / drug therapy*
Candidiasis, Oral / microbiology
Caspofungin
Drug Resistance, Fungal*
Echinocandins
Endophthalmitis / drug therapy*
Endophthalmitis / microbiology
Female
Fungemia / drug therapy*
Fungemia / microbiology
Humans
Lipopeptides
Microbial Sensitivity Tests
Peptides, Cyclic / pharmacology*
Peptides, Cyclic / therapeutic use

Substances

Antifungal Agents
Echinocandins
Lipopeptides
Peptides, Cyclic
Caspofungin